Università degli Studi di Firenze, Firenze, Italy.
J Psychopharmacol. 2010 Aug;24(8):1269-72. doi: 10.1177/0269881108098822. Epub 2008 Nov 14.
We report the successful treatment of a case of refractory binge eating disorder (BED) with duloxetine, a combined serotonin and norepinephrine reuptake inhibitor, resulting in complete remission of the patient's bingeing behaviours. This case is discussed in the context of the existing literature on the psychopharmacology of BED. Results demonstrate that inhibition of 5-HT and noradrenaline reuptake by duloxetine markedly reduces food intake, suggesting that this may be a novel approach for the treatment of obesity.
我们报告了一例使用度洛西汀（一种同时抑制 5-羟色胺和去甲肾上腺素再摄取的药物）成功治疗难治性暴食障碍（BED）的案例，该药物治疗使患者的暴食行为完全缓解。本文结合 BED 的精神药理学现有文献对该病例进行了讨论。结果表明，度洛西汀抑制 5-羟色胺和去甲肾上腺素再摄取可显著减少食物摄入，提示这可能是治疗肥胖的一种新方法。
